Today's top medical abstracts
Internal Med
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Internal Med
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Internal Med
        Academic Med/Education
        Adolescent Medicine
        Allergy/Immunology
        Atherosclerosis/Lipids
        Basic Science/Genetics
        Cardiology
        Clinical Pharmacology
        Complementary Medicine
        Critical Care/
    Hospitalist
        Dermatology
        Economics of Medicine
        Endocrinology
        Epidemiology
        Gastroenterology
        Geriatrics
        Hematology/Oncology
        Infectious Disease
        Nephrology/Urology
        Neurology
        Orthopedic/Physical Med
        Popular Press
        Preventive Medicine
        Primary Care
        Psychiatry
        Pulmonology
        Radiology/Diagnostics
        Rheumatology
        Sports Medicine
        Vascular Medicine
        Women`s Health
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
Cancer Science: #14. Does Size Matter? "Stumpy" Telomeres Allow Cancer Cells to Evade Senescence
Sara Hartley, MDLinx Oncology
  See all
Gastric cancer Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Overexpression of dihydrodiol dehydrogenase as a prognostic marker in resected gastric cancer patients
Digestive Diseases and Sciences, 07/14/08
Print     Email This Article     Save in My Library   Free Abstract
Chang HC et al. - Dihydrodiol dehydrogenase (DDH) expression may be useful in identifying high-risk gastric cancer patients and distinguishing future candidates for curative and palliative treatment.

Methods
  • Study to evaluate the (i) correlation between clinicopathological data and DDH expression and (ii) the prognostic significance of DDH expression in pts with resected gastric cancer
  • 81 pts who received surgical treatment for gastric cancer were enrolled
  • Pathology samples were immunostained with monoclonal antibody to DDH
  • The relationship between DDH expression and clinicopathological data was analyzed by chi-square analysis
  • Survival curves were plotted using the Kaplan–Meier method and compared using a log-rank test

Results
  • The overexpression rate of DDH was 41.9%
  • Of pts with overexpressed DDH, 13% had stage I, 24% had stage II, 52% had stage III, and 78% had stage IV tumors
  • Among pts who died, DDH expression level differed between high and low-expression groups
  • Survival was better in pts with low DDH expression

Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.